ACUTE TOXICITY OF THE DRUG THIOCINE IN EXPERIMENTAL STUDIES

Abstract

In each country, the incidence of obesity is constantly increasing, and dyslipidemia often occurs in parallel. Every year, around 2.8 million people worldwide die due to being overweight or obese. If the current trend continues, by 2030, 86.3% of adults will be overweight, and the number of deaths will be very high [1]. Therefore, currently, there is a growing interest worldwide in the search for new drugs or substances that reduce dyslipidemic indicators and studying their properties. Dyslipidemias are an active and expanding area of research, with recent studies providing insight into their molecular basis and genetic origin. These studies determine their role in the development of atherosclerosis and elucidate the ability of pharmacological agents to reduce the risk of cardiovascular disease in affected individuals.